Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development.
França CT, White MT, He WQ, Hostetler JB, Brewster J, Frato G, Malhotra I, Gruszczyk J, Huon C, Lin E, Kiniboro B, Yadava A, Siba P, Galinski MR, Healer J, Chitnis C, Cowman AF, Takashima E, Tsuboi T, Tham WH, Fairhurst RM, Rayner JC, King CL, Mueller I. França CT, et al. Among authors: yadava a. Elife. 2017 Sep 26;6:e28673. doi: 10.7554/eLife.28673. Elife. 2017. PMID: 28949293 Free PMC article.
Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.
Lumsden JM, Pichyangkul S, Srichairatanakul U, Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S, Klein J, Bertholet S, Vedvick TS, Reed SG, Sattabongkot J, Bennett JW, Polhemus ME, Ockenhouse CF, Howard RF, Yadava A. Lumsden JM, et al. Among authors: yadava a. Infect Immun. 2011 Sep;79(9):3492-500. doi: 10.1128/IAI.05257-11. Epub 2011 Jun 20. Infect Immun. 2011. PMID: 21690242 Free PMC article.
Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
Lumsden JM, Nurmukhambetova S, Klein JH, Sattabongkot J, Bennett JW, Bertholet S, Fox CB, Reed SG, Ockenhouse CF, Howard RF, Polhemus ME, Yadava A. Lumsden JM, et al. Among authors: yadava a. Vaccine. 2012 May 9;30(22):3311-9. doi: 10.1016/j.vaccine.2012.03.004. Epub 2012 Mar 13. Vaccine. 2012. PMID: 22425788
Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
Bennett JW, Yadava A, Tosh D, Sattabongkot J, Komisar J, Ware LA, McCarthy WF, Cowden JJ, Regules J, Spring MD, Paolino K, Hartzell JD, Cummings JF, Richie TL, Lumsden J, Kamau E, Murphy J, Lee C, Parekh F, Birkett A, Cohen J, Ballou WR, Polhemus ME, Vanloubbeeck YF, Vekemans J, Ockenhouse CF. Bennett JW, et al. Among authors: yadava a. PLoS Negl Trop Dis. 2016 Feb 26;10(2):e0004423. doi: 10.1371/journal.pntd.0004423. eCollection 2016 Feb. PLoS Negl Trop Dis. 2016. PMID: 26919472 Free PMC article. Clinical Trial.
Asymptomatic Plasmodium vivax infections induce robust IgG responses to multiple blood-stage proteins in a low-transmission region of western Thailand.
Longley RJ, França CT, White MT, Kumpitak C, Sa-Angchai P, Gruszczyk J, Hostetler JB, Yadava A, King CL, Fairhurst RM, Rayner JC, Tham WH, Nguitragool W, Sattabongkot J, Mueller I. Longley RJ, et al. Among authors: yadava a. Malar J. 2017 Apr 28;16(1):178. doi: 10.1186/s12936-017-1826-8. Malar J. 2017. PMID: 28454546 Free PMC article.
42 results